Shares of Exelixis, Inc. EXEL gained 7.4% on June 23, after the company announced positive top-line results from the late-stage STELLAR-303 study. This phase III study is a global, multicenter, ...

Startups unveiled original IP rooted in Saudi stories but built for global markets. Merak Capital’s $80m Gaming Fund powers the accelerator’s long-term vision. Exel provides equity investment, ...

Thank you for being here today at the 2025 Citi Biopharma Conference in Boston. Happy to have with us this afternoon. our good friends from Exelixis, Michael, I guess you could just introduce yourself ...

Exelixis’ (EXEL) lead drug, Cabometyx, a tyrosine kinase inhibitor (TKI), is one of the leading drugs for the treatment of renal cell carcinoma (RCC). The FDA approval for the label expansion of ...

LOS ANGELES, Sept. 4, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Exelixis, Inc.

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Exelixis, Inc. (“Exelixis” or “the Company”) (NASDAQ: EXEL) for ...

HP partners with Exel by Merak to drive talent development, industry collaboration, and innovation in Saudi Arabia’s gaming sector. This partnership integrates HP’s courses and learning programs into ...

CABOMETYX remains the leading TKI in renal cell carcinoma, driving strong revenue growth and expanding into new indications like neuroendocrine tumors. Exelixis's pipeline, led by zanzalintinib, shows ...

DENVER -- Point guard Nick Van Exel is still a member of the Denver Nuggets, and may not be going anywhere for a while. While Van Exel is willing to "rework or restructure" the final two years of his ...